Vor Biopharma Inc. (VOR)

Market Cap	122.79M
Revenue (ttm)	n/a
Net Income (ttm)	-117.86M
Shares Out	68.22M
EPS (ttm)	-1.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	138,367
Open	1.810
Previous Close	1.760
Day's Range	1.760 - 1.840
52-Week Range	1.620 - 5.700
Beta	-0.37
Analysts	Strong Buy
Price Target	14.25 (+691.67%)
Earnings Date	May 13, 2024

About VOR

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 168
• Stock Exchange: NASDAQ
• Ticker Symbol: VOR

Analyst Forecast

According to 6 analysts, the average rating for VOR stock is "Strong Buy." The 12-month stock price forecast is $14.25, which is an increase of 691.67% from the latest price.

Price Target

$14.25

(691.67% upside)

Analyst Consensus: Strong Buy